1
|
Nagini S: Carcinoma of the stomach: A
review of epidemiology, pathogenesis, molecular genetics and
chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
3
|
Yagi K, Nozawa Y, Endou S and Nakamura A:
Diagnosis of early gastric cancer by magnifying endoscopy with NBI
from viewpoint of histological imaging: Mucosal patterning in terms
of white zone visibility and its relationship to histology. Diagn
Ther Endosc. 2012:9548092012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Boku N: Past and present achievements, and
future direction of the Gastrointestinal Oncology Study Group
(GIOSG), a Division of Japan Clinical Oncology Group (JCOG). Jpn J
Clin Oncol. 41:1315–1321. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Boku N: HER2-positive gastric cancer.
Gastric Cancer. 17:1–12. 2014. View Article : Google Scholar :
|
6
|
Zhou Y, Gunput RA and Pasterkamp RJ:
Semaphorin signaling: Progress made and promises ahead. Trends
Biochem Sci. 33:161–170. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rehman M and Tamagnone L: Semaphorins in
cancer: Biological mechanisms and therapeutic approaches. Semin
Cell Dev Biol. 24:179–189. 2013. View Article : Google Scholar
|
8
|
Gu C, Yoshida Y, Livet J, Reimert DV, Mann
F, Merte J, Henderson CE, Jessell TM, Kolodkin AL and Ginty DD:
Semaphorin 3E and plexin-D1 control vascular pattern independently
of neuropilins. Science. 307:265–268. 2005. View Article : Google Scholar
|
9
|
Moriya J, Minamino T, Tateno K, Okada S,
Uemura A, Shimizu I, Yokoyama M, Nojima A, Okada M, Koga H, et al:
Inhibition of semaphorin as a novel strategy for therapeutic
angiogenesis. Circ Res. 106:391–398. 2010. View Article : Google Scholar
|
10
|
Roodink I, Raats J, van der Zwaag B,
Verrijp K, Kusters B, van Bokhoven H, Linkels M, de Waal RM and
Leenders WP: Plexin D1 expression is induced on tumor vasculature
and tumor cells: A novel target for diagnosis and therapy? Cancer
Res. 65:8317–8323. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Casazza A, Finisguerra V, Capparuccia L,
Camperi A, Swiercz JM, Rizzolio S, Rolny C, Christensen C, Bertotti
A, Sarotto I, et al: Sema3E-Plexin D1 signaling drives human cancer
cell invasiveness and metastatic spreading in mice. J Clin Invest.
120:2684–2698. 2010. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Tseng CH, Murray KD, Jou MF, Hsu SM, Cheng
HJ and Huang PH: Sema3E/plexin-D1 mediated
epithelial-to-mesenchymal transition in ovarian endometrioid
cancer. PLoS One. 6:e193962011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Luchino J, Hocine M, Amoureux MC, Gibert
B, Bernet A, Royet A, Treilleux I, Lécine P, Borg JP, Mehlen P, et
al: Semaphorin 3E suppresses tumor cell death triggered by the
plexin D1 dependence receptor in metastatic breast cancers. Cancer
Cell. 24:673–685. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al; Australian Pancreatic Cancer Genome Initiative. Pancreatic
cancer genomes reveal aberrations in axon guidance pathway genes.
Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Japanese Gastric Cancer Association.
Japanese classification of gastric carcinoma: 3rd English edition.
Gastric Cancer. 14:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Christensen C, Ambartsumian N, Gilestro G,
Thomsen B, Comoglio P, Tamagnone L, Guldberg P and Lukanidin E:
Proteolytic processing converts the repelling signal Sema3E into an
inducer of invasive growth and lung metastasis. Cancer Res.
65:6167–6177. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Chen H, Xie GH, Wang WW, Yuan XL, Xing WM,
Liu HJ, Chen J, Dou M and Shen LS: Epigenetically downregulated
Semaphorin 3E contributes to gastric cancer. Oncotarget.
6:20449–20465. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Movassagh H, Shan L, Halayko AJ, Roth M,
Tamm M, Chakir J and Gounni AS: Neuronal chemorepellent Semaphorin
3E inhibits human airway smooth muscle cell proliferation and
migration. J Allergy Clin Immunol. 133:560–567. 2014. View Article : Google Scholar
|
19
|
Tang C, Gao X, Liu H, Jiang T and Zhai X:
Decreased expression of SEMA3A is associated with poor prognosis in
gastric carcinoma. Int J Clin Exp Pathol. 7:4782–4794.
2014.PubMed/NCBI
|
20
|
Pan G, Zhu Z, Huang J, Yang C, Yang Y,
Wang Y, Tuo X, Su G, Zhang X, Yang Z, et al: Semaphorin 5A promotes
gastric cancer invasion/metastasis via urokinase-type plasminogen
activator/phosphoinositide 3-kinase/protein kinase B. Dig Dis Sci.
58:2197–2204. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Miyato H, Tsuno NH and Kitayama J:
Semaphorin 3C is involved in the progression of gastric cancer.
Cancer Sci. 103:1961–1966. 2012. View Article : Google Scholar : PubMed/NCBI
|